Hepatic sarcoidosis associated with pegylated interferon alfa therapy for chronic hepatitis C: case report and review of literature.
Adla
Mahathi
M
Division of Gastroenterology, Hepatology & Nutrition, University of Pittsburgh, Pittsburgh, PA 15213, USA.
Downey
Kathy K
KK
Ahmad
Jawad
J
D000328:Adult; D000998:Antiviral Agents / Q000009:adverse effects / Q000627:therapeutic use; D001706:Biopsy; D056486:Chemical and Drug Induced Liver Injury; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects* / Q000627:therapeutic use*; D008099:Liver / Q000473:pathology; D008107:Liver Diseases / Q000097:blood / Q000175:diagnosis*; D008297:Male; D007703:Peptidyl-Dipeptidase A / Q000097:blood; D011092:Polyethylene Glycols; D011994:Recombinant Proteins; D012254:Ribavirin / Q000009:adverse effects / Q000627:therapeutic use; D012507:Sarcoidosis / Q000097:blood / Q000139:chemically induced* / Q000175:diagnosis*
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; D007703:Peptidyl-Dipeptidase A; C417083:peginterferon alfa-2b